Gotistobart  (Synonyms: ONC-392; BNT 316)

Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CTLA4

Gotistobart exerts an immunotherapeutic effect by selectively depleting regulatory T cells (Treg) in the tumor microenvironment and exhibits reduced toxicity relative to existing anti-CTLA-4 antibodies in preclinical settings^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1493  [NCBI]

P16410

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.22 kDa

2226344-78-9

Liquid

Colorless to light yellow

[Gotistobart]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow Cytometry analysis of Ramos cells labelling CTLA4 (red) with Gotistobart (anti-CTLA4) (HY-P990042). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. He K, et al. Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD (L) 1-targeted immunotherapy[J]. 2023.